FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

Carillon Eagle Growth & Income Fund highlighted stocks like AstraZeneca PLC (NASDAQ:AZN) in the second quarter 2024 investor letter. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company ...

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other 52-week high stocks. The U.S. stock market has been on a roll, with major indices ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs ...

Qiagen and AstraZeneca are expanding their diagnostics partnership, with plans to explore the use of genomic profiling in chronic diseases beyond cancer. The long-time collaborators, which ...

For the 2024–2025 season, all influenza vaccines will be trivalent. The Centers for Disease ... Fluad (standard dose with MF59 adjuvant), and FluMist intranasal spray. Cell culture-based or ...

AstraZeneca has beaten all healthcare-focused ETFs. The stock is up by over 27% this year, helped by its oncology business. It has gotten highly overbought, meaning that a pullback is coming ...

Chris Nemeth, 51, worked in airline logistics until he got the AstraZeneca vaccine in July 2021 and developed chronic inflammatory demyelinating polyneuropathy (CIPD) which can cause numbness ...

Background Because inactivated trivalent influenza vaccines (TIVs) contain 1 influenza B strain, whereas 2 lineages may co-circulate, B lineage mismatch is frequent. We assessed an inactivated ...

Influenza (trivalent) vaccine is under clinical development by Novavax and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II drugs for Seasonal Influenza have a 30% phase ...